Printed From:

PRALUENT® (alirocumab) Mechanism of Action

PCSK9 inhibition works differently than statins1

Without PCSK9 inhibition

LDLR Without PCKS9 Inhibitor

With PRALUENT PCSK9 inhibition

LDLR With PCKS9 Inhibitor
  • PCSK9 decreases the number of available LDL receptors, resulting in higher LDL-C levels2
  • PCSK9 inhibition with PRALUENT increases the number of available LDL receptors, resulting in lower LDL-C levels2

PCSK9 inhibition with PRALUENT increases the number of available LDL receptors to clear LDL-C, resulting in lower LDL-C levels2

NEED HELP? CONTACT A REP

Learn more about PCSK9 inhibition with PRALUENT from a PRALUENT Field Representative

Contact a rep

APPROPRIATE PATIENTS

See if patients in your practice are right for PRALUENT

Find out now

THE POWER OF PRALUENT

Get more information on the efficacy of PRALUENT in clinical trials

View efficacy

References:

  1. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2017 focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk. J Am Coll Cardiol. 2017. doi: 10.1016/j.jacc.2017.07.745.
  2. PRALUENT® (alirocumab) Prescribing Information. Sanofi and Regeneron Pharmaceuticals.